Page 4 - Benevolent Platform News Today

/PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary...

/PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary...

-- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery...

- Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the

IPF is a chronic and ultimately fatal disease that causes lung tissue to stiffen, leading to permanent lung scarring that makes it harder to breathe

BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective

This release may contain forward-looking statements. Forward-looking statements are statements that are not...

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target - AI-generated target was identified through The Benevolent Platform and AstraZenecas scientific expertise and rich datasets LONDON, Jan. 27, 2021 /PRNewswire/ -- BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target f...